These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11522122)

  • 21. [Therapy of mixed urinary incontinence].
    Goepel M
    Urologe A; 2003 Jun; 42(6):812-7. PubMed ID: 12851773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms.
    Ho CH; Chang TC; Lin HH; Liu SP; Huang KH; Yu HJ
    J Formos Med Assoc; 2010 Oct; 109(10):702-8. PubMed ID: 20970066
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.
    Anderson RU; MacDiarmid S; Kell S; Barada JH; Serels S; Goldberg RP
    Int Urogynecol J Pelvic Floor Dysfunct; 2006 Sep; 17(5):502-11. PubMed ID: 16724169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients.
    Takei M; Homma Y;
    Int J Urol; 2005 May; 12(5):456-64. PubMed ID: 15948744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does gender or age affect the efficacy and safety of tolterodine?
    Michel MC; Schneider T; Krege S; Goepel M
    J Urol; 2002 Sep; 168(3):1027-31. PubMed ID: 12187215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan.
    D'Souza AO; Smith MJ; Miller LA; Doyle J; Ariely R
    J Manag Care Pharm; 2008 Apr; 14(3):291-301. PubMed ID: 18439051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study.
    Agarwal A; Dhiraaj S; Singhal V; Kapoor R; Tandon M
    Br J Anaesth; 2006 Mar; 96(3):377-80. PubMed ID: 16415311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tolterodine.
    Hills CJ; Winter SA; Balfour JA
    Drugs; 1998 Jun; 55(6):813-20; discussion 821-2. PubMed ID: 9617596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and tolerability of tolterodine for the treatment of overactive bladder in adults.
    Roberts RG; Garely AD; Bavendam T
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S158-62. PubMed ID: 16161389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tolterodine-associated acute mixed liver injury.
    Schlienger RG; Keller MJ; Krähenbühl S
    Ann Pharmacother; 2002 May; 36(5):817-9. PubMed ID: 11978158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Visual hallucinations at the onset of tolterodine treatment in a patient with a high-level spinal cord injury.
    Malavaud B; Bagheri H; Senard JM; Sarramon JP
    BJU Int; 1999 Dec; 84(9):1109. PubMed ID: 10571650
    [No Abstract]   [Full Text] [Related]  

  • 34. Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors.
    Edwards KR; O'Connor JT
    J Am Geriatr Soc; 2002 Jun; 50(6):1165-6. PubMed ID: 12110086
    [No Abstract]   [Full Text] [Related]  

  • 35. Tolterodine--a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data.
    Nilvebrant L; Hallén B; Larsson G
    Life Sci; 1997; 60(13-14):1129-36. PubMed ID: 9121357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative adherence to oxybutynin or tolterodine among older patients.
    Gomes T; Juurlink DN; Mamdani MM
    Eur J Clin Pharmacol; 2012 Jan; 68(1):97-9. PubMed ID: 21710237
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Probable interaction between tolterodine and warfarin.
    Taylor JR
    Pharmacotherapy; 2006 May; 26(5):719-21. PubMed ID: 16718947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
    Abrams P; Kaplan S; De Koning Gans HJ; Millard R
    J Urol; 2006 Mar; 175(3 Pt 1):999-1004; discussion 1004. PubMed ID: 16469601
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Failure of tolterodine to treat clozapine-induced nocturnal enuresis.
    English BA; Still DJ; Harper J; Saklad SR
    Ann Pharmacother; 2001; 35(7-8):867-9. PubMed ID: 11485135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
    Roehrborn CG; Abrams P; Rovner ES; Kaplan SA; Herschorn S; Guan Z
    BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.